Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from LifeVantage ( (LFVN) ) is now available.
On January 30, 2026, LifeVantage announced that President and CEO Steven R. Fife plans to retire from his roles, including his board seat, with his resignation expected to take effect in April 2026, and the company emphasized that his decision was not related to any dispute over operations or financial policies. On February 4, 2026, the company reported that second-quarter fiscal 2026 revenue for the period ended December 31, 2025 fell 27.8% year on year to $48.9 million, with sharp declines in Americas sales and softer performance in Asia/Pacific and Europe, as the business cycled last year’s launch of the MindBody GLP-1 System™ and recorded lower profitability, including net income of $0.3 million, or $0.02 per diluted share, and adjusted EBITDA of $3.9 million. Management acknowledged competitive pressure in the weight-loss market and weaker-than-expected results, but pointed to growing momentum in the recently acquired LoveBiome® line, planned international expansion and new product launches as levers to restore growth, even as cash generation and cash balances declined over the first half of fiscal 2026 and gross margins were hit by inventory obsolescence tied to the GLP-1 product. Despite the earnings pressure, LifeVantage signaled confidence in its long-term strategy by unveiling a new $60 million share repurchase program to run through 2027, declaring a quarterly dividend of $0.045 per share payable March 16, 2026, and reiterating full-year fiscal 2026 guidance that foresees $185 million to $200 million in revenue and improved adjusted profitability, framing the current year as a transition period focused on portfolio diversification and shareholder returns.
The most recent analyst rating on (LFVN) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on LifeVantage stock, see the LFVN Stock Forecast page.
Spark’s Take on LFVN Stock
According to Spark, TipRanks’ AI Analyst, LFVN is a Neutral.
LifeVantage’s overall stock score reflects a mix of strong financial performance and attractive valuation, offset by bearish technical indicators and some operational challenges highlighted in the earnings call. The company’s strategic initiatives, particularly in the gut health market, provide a positive outlook, but maintaining operational efficiency and addressing cost pressures will be key to future success.
To see Spark’s full report on LFVN stock, click here.
More about LifeVantage
LifeVantage Corporation (Nasdaq: LFVN), founded in 2003 and headquartered in Lehi, Utah, is a health and wellness company specializing in nutrigenomics, offering scientifically validated products that activate cellular health processes. Its portfolio includes the Protandim® family, TrueScience® Liquid Collagen and skin and hair care lines, the MindBody GLP-1 System™, gut health product P84, various nutritional activators, AXIO® nootropic energy drinks, and Petandim® for dogs, which are sold primarily through a network of independent consultants to customers in the Americas, Asia/Pacific, and Europe.
Average Trading Volume: 199,747
Technical Sentiment Signal: Sell
Current Market Cap: $69.98M
Find detailed analytics on LFVN stock on TipRanks’ Stock Analysis page.